QQQ   296.07 (+0.93%)
AAPL   146.19 (+1.55%)
MSFT   247.98 (+-0.01%)
META   151.91 (+3.13%)
GOOGL   99.38 (+1.91%)
AMZN   101.67 (+2.47%)
TSLA   175.90 (+9.75%)
NVDA   203.58 (+2.81%)
NIO   12.95 (+6.41%)
BABA   119.00 (-1.30%)
AMD   76.00 (+1.12%)
T   19.88 (-0.60%)
MU   63.50 (+1.11%)
F   13.30 (+2.94%)
CGC   2.95 (+6.88%)
GE   83.33 (+2.70%)
DIS   109.86 (+0.15%)
AMC   5.34 (+1.14%)
PFE   44.10 (-0.34%)
PYPL   82.05 (+1.53%)
NFLX   362.46 (-0.66%)
QQQ   296.07 (+0.93%)
AAPL   146.19 (+1.55%)
MSFT   247.98 (+-0.01%)
META   151.91 (+3.13%)
GOOGL   99.38 (+1.91%)
AMZN   101.67 (+2.47%)
TSLA   175.90 (+9.75%)
NVDA   203.58 (+2.81%)
NIO   12.95 (+6.41%)
BABA   119.00 (-1.30%)
AMD   76.00 (+1.12%)
T   19.88 (-0.60%)
MU   63.50 (+1.11%)
F   13.30 (+2.94%)
CGC   2.95 (+6.88%)
GE   83.33 (+2.70%)
DIS   109.86 (+0.15%)
AMC   5.34 (+1.14%)
PFE   44.10 (-0.34%)
PYPL   82.05 (+1.53%)
NFLX   362.46 (-0.66%)
QQQ   296.07 (+0.93%)
AAPL   146.19 (+1.55%)
MSFT   247.98 (+-0.01%)
META   151.91 (+3.13%)
GOOGL   99.38 (+1.91%)
AMZN   101.67 (+2.47%)
TSLA   175.90 (+9.75%)
NVDA   203.58 (+2.81%)
NIO   12.95 (+6.41%)
BABA   119.00 (-1.30%)
AMD   76.00 (+1.12%)
T   19.88 (-0.60%)
MU   63.50 (+1.11%)
F   13.30 (+2.94%)
CGC   2.95 (+6.88%)
GE   83.33 (+2.70%)
DIS   109.86 (+0.15%)
AMC   5.34 (+1.14%)
PFE   44.10 (-0.34%)
PYPL   82.05 (+1.53%)
NFLX   362.46 (-0.66%)
QQQ   296.07 (+0.93%)
AAPL   146.19 (+1.55%)
MSFT   247.98 (+-0.01%)
META   151.91 (+3.13%)
GOOGL   99.38 (+1.91%)
AMZN   101.67 (+2.47%)
TSLA   175.90 (+9.75%)
NVDA   203.58 (+2.81%)
NIO   12.95 (+6.41%)
BABA   119.00 (-1.30%)
AMD   76.00 (+1.12%)
T   19.88 (-0.60%)
MU   63.50 (+1.11%)
F   13.30 (+2.94%)
CGC   2.95 (+6.88%)
GE   83.33 (+2.70%)
DIS   109.86 (+0.15%)
AMC   5.34 (+1.14%)
PFE   44.10 (-0.34%)
PYPL   82.05 (+1.53%)
NFLX   362.46 (-0.66%)
NYSE:PEN

Penumbra - PEN Stock Forecast, Price & News

$249.68
+5.10 (+2.09%)
(As of 01/27/2023 01:33 PM ET)
Add
Compare
Today's Range
$242.05
$251.42
50-Day Range
$191.28
$250.63
52-Week Range
$114.86
$253.22
Volume
132,667 shs
Average Volume
318,487 shs
Market Capitalization
$9.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$238.55

Penumbra MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3.0% Downside
$238.55 Price Target
Short Interest
Bearish
10.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
0.25mentions of Penumbra in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$5.64 M Sold Last Quarter
Proj. Earnings Growth
600.00%
From $0.14 to $0.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

569th out of 1,055 stocks

Surgical & Medical Instruments Industry

58th out of 105 stocks


PEN stock logo

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Penumbra (NYSE:PEN) Reaches New 1-Year High at $245.17
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates
Citigroup Downgrades Penumbra to Neutral
7 Analysts Have This to Say About Penumbra
Analyst Ratings for Penumbra
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings
11/03/2022
Today
1/27/2023
Next Earnings (Confirmed)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$238.55
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$185.00
Forecasted Upside/Downside
-4.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$5.28 million
Pretax Margin
-5.32%

Debt

Sales & Book Value

Annual Sales
$747.59 million
Cash Flow
$1.20 per share
Book Value
$25.53 per share

Miscellaneous

Free Float
35,890,000
Market Cap
$9.48 billion
Optionable
Optionable
Beta
0.48

Key Executives

  • Adam ElsesserAdam Elsesser
    Chairman, President & Chief Executive Officer
  • Ben Sorci
    Executive Vice President-Operations
  • Maggie S. Yuen
    Chief Financial Officer
  • Pankaj Tiwari
    Chief Information Officer & Executive VP
  • Michaella Corso
    Vice President-Clinical Affairs













PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price forecast for 2023?

12 brokers have issued 12 month price targets for Penumbra's stock. Their PEN share price forecasts range from $185.00 to $300.00. On average, they predict the company's share price to reach $238.55 in the next year. This suggests that the stock has a possible downside of 2.5%.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2023?

Penumbra's stock was trading at $222.46 at the beginning of 2023. Since then, PEN stock has increased by 9.9% and is now trading at $244.58.
View the best growth stocks for 2023 here
.

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our PEN earnings forecast
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) announced its quarterly earnings results on Thursday, November, 3rd. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The company had revenue of $213.68 million for the quarter, compared to analyst estimates of $212.41 million. Penumbra had a negative net margin of 3.68% and a positive trailing twelve-month return on equity of 0.45%.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $840.00 million-$845.00 million, compared to the consensus revenue estimate of $860.97 million.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.32%), Allspring Global Investments Holdings LLC (0.44%), AEGON ASSET MANAGEMENT UK Plc (0.18%), Oak Harbor Wealth Partners LLC (0.09%), Yousif Capital Management LLC (0.05%) and Comerica Bank (0.04%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $244.58.

How much money does Penumbra make?

Penumbra (NYSE:PEN) has a market capitalization of $9.29 billion and generates $747.59 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Penumbra have?

The company employs 3,800 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 1/27/2023 by MarketBeat.com Staff